Document is current
Any future updates will be listed below
-
Authors
Aziz, Faisal
Tripolt, Norbert J.
Pferschy, Peter N.
Kolesnik, Ewald
Mangge, Harald
Curcic, Pero
Hermann, Markus
Meinitzer, Andreas
von Lewinski, Dirk
Sourij, Harald
,
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03087773 at ClinicalTrials.govDocuments that mention this clinical trial
New drugs in preclinical and early stage clinical development in the treatment of heart failure
https://doi.org/10.1080/13543784.2019.1551357
Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial
https://doi.org/10.1186/s12933-023-01920-6
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim (1245.151)
- License Information
-
More Information
Article History
Received: 15 May 2023
Accepted: 11 July 2023
First Online: 20 July 2023
Declarations
:
: The EMMY trial was approved by the Ethics committee of the Medical University of Graz, Austria (EK 29-179 ex16/17, EudraCT 2016-004591-22) and registered at ClinicalTrials.gov (NCT03087773). The trial conformed to the 1964 Declaration of Helsinki and adhered to the guidelines of Good Clinical Practice (ICH GCP E6). All study participants provided written consent.
: All authors consent for the publication of this study.
: HS is on the advisory board and speakers bureau of Boehringer Ingelheim, NovoNordisk, Sanofi-Aventis, Amgen, AstraZeneca, Bayer, Eli Lilly, Kapsch, MSD, and Daiichi Sankyo. DvL is on the advisory board and speaker’s bureau of by Boehringer Ingelheim, Novartis, Sanova, Sanofi, Orion, AstraZeneca, Bayer Recardio, Vaxxinity and Daiichi Sankyo. FA reports no conflict of interest related to this study. All other authors report no conflict of interest related to this study.
